According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Separately, HC Wainwright restated a buy rating and issued a $8.00 target price (down previously from $11.00) on shares of Vical in a report on Thursday, September 22nd.
Shares of Vical (NASDAQ:VICL) opened at 3.03 on Wednesday. The company’s market cap is $27.89 million. Vical has a one year low of $2.80 and a one year high of $5.40. The stock’s 50 day moving average price is $3.40 and its 200-day moving average price is $3.97.
Vical (NASDAQ:VICL) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.14. The company had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $4.50 million. Vical had a negative net margin of 30.81% and a negative return on equity of 14.18%. On average, analysts expect that Vical will post ($0.86) EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the company’s stock valued at $811,000 after buying an additional 476,499 shares during the period. ClariVest Asset Management LLC acquired a new position in Vical during the second quarter valued at approximately $208,000. Eagle Global Advisors LLC acquired a new position in Vical during the second quarter valued at approximately $178,000. Finally, BlackRock Fund Advisors increased its position in Vical by 32.5% in the second quarter. BlackRock Fund Advisors now owns 23,459 shares of the company’s stock valued at $106,000 after buying an additional 5,750 shares during the period. 31.47% of the stock is owned by institutional investors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.